Constitutive and Induced CD44 Shedding by ADAM-Like Proteases and Membrane-Type 1 Matrix Metalloproteinase

Cancer Research

Volumn 64, Issue 3, 2004, Pages 876-882

  Nakamura, Hiroyuki ^a   Suenaga, Naoko ^a   Taniwaki, Kaori ^a   Matsuki, Hirokazu ^a,b   Yonezawa, Kayoko ^b   Fujii, Masato ^c   Okada, Yasunori ^c   Seiki, Motoharu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Daiichi Fine Chemical Co Ltd   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM LIKE PROTEASE; ANTIBODY; ANTIGEN; CD44H ANTIGEN; DISINTEGRIN; HERMES ANTIGEN; HYALURONIC ACID; LIGAND; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; PROTEIN; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL; CANCER INVASION; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ADAM PROTEINS; AMINO ACID SEQUENCE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIBODY SPECIFICITY; ANTIGENS, CD44; CELL LINE, TUMOR; HUMANS; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MELANOMA; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS;

EID: 0842347494     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3502     Document Type: Article

References (34)

1. Ponta, H., Sherman, L., and Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell. Biol., 4: 33-45, 2003.
2. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B., and Seed, B. CD44 is the principal cell surface receptor for hyaluronate. Cell, 61: 1303-1313, 1990.
3. Lee, J. Y., and Spicer, A. P. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr. Opin. Cell Biol., 12: 581-586, 2000.
4. Naot, D., Sionov, R. V., and Ish-Shalom, D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res., 71: 241-319, 1997.
5. Wolff, E. A., Greenfield, B., Taub, D. D., Murphy, W. J., Bennett, K. L., and Aruffo, A. Generation of artificial proteoglycans containing glycosaminoglycan-modified D44. Demonstration of the interaction between rantes and chondroitin sulfate. J. Biol. Chem., 274, 2518-2524, 1999.
6. Yu, Q., and Stamenkovic, I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev., 13: 35-48, 1999.
7. Yu, W. H., Woessner, J. F., Jr., McNeish, J. D., and Stamenkovic, I. CD44 anchors the assembly of matrylsin/MMP-7 with heparin-binding epidermal growth factor precursor ErbB4 and regulates female reproductive organ remodeling. Genes Dev., 16: 307-323, 2002.
8. Mori, H., Tomari, T., Koshikawa, N., Kajita, M., Itoh, Y., Sato, H., Tojo, H., Yana, I., and Seiki, M. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J., 21: 3949-3959, 2002.
9. Seiki, M. The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr. Opin. Cell Biol., 14: 624-632, 2002.
10. Agnihotri, R., Crawford, H. C., Haro, H., Matrisian, L. M., Havrda, M. C., and Liaw, L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J. Biol. Chem., 276: 28261-28267, 2001.
11. Yu, Q., and Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev., 14: 163-176, 2000.
12. Seiki, M., Koshikawa, N., and Yana, I. Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Metastisis Rev., 22: 129-143, 2003.
13. Goebeler, M., Kaufmann, D., Brocker, E. B., and Klein, C. E. Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J. Cell Sci., 109: 1957-1964, 1996.
14. Okamoto, I., Kawano, Y., Tsuiki, H., Sasaki, J., Nakao, M., Matsumoto, M., Suga, M., Ando, M., Nakajima, M., and Saya, H. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene, 18: 1435-1446, 1999.
15. Kajita, M., Itoh, Y., Chiba, T., Mori, H., Okada, A., Kinoh, H., and Seiki, M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol., 153: 893-904, 2001.
16. Haynes, B. F., Hale, L. P., Patton, K. L., Martin, M. E., and McCallum, R. M. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum., 34: 1434-1443, 1991.
17. Haberhauer, G., Kittl, E. M., Skoumal, M., Hubl, W., Wagner, E., Bayer, P. M., Bauer, K., and Dunky, A. Increased serum levels of soluble CD44-isoform v5 in rheumatic diseases are restricted to seropositive rheumatoid arthritis. Acta Med. Austriaca, 24: 23-25, 1997.
18. Kittl, E. M., Haberhauer, G., Ruckser, R., Selleny, S., Rech-Weichselbraun, I., Hinterberger, W., and Bauer, K. Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Rheumatol. Int., 16: 181-186, 1997.
19. Guo, Y. J., Liu, G., Wang, X., Jin, D., Wu, M., Ma, J., and Sy, M. S. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res., 54: 422-426, 1994.
20. Masson, D., Denis, M. G., Denis, M., Blanchard, D., Loirat, M. J., Cassagnau, E., and Lustenberger, P. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Br. J. Cancer, 80: 1995-2000, 1999.
21. Yamane, N., Tsujitani, S., Makino, M., Maeta, M., and Kaibara, N. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer. Oncology, 56: 232-238, 1999.
22. Okamoto, I., Tsuiki, H., Kenyon, L. C., Godwin, A. K., Emlet, D. R., Holgado-Madruga, M., Lanham, I. S., Joynes, C. J., Vo, K. T., Guha, A., Matsumoto, M., Ushio, Y., Saya, H., and Wong, A. J. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am. J. Pathol., 160: 441-447, 2002.
23. Inoue, A., Narumi, K., Matsubara, N., Sugawara, S., Saijo, Y., Satoh, K., and Nukiwa, T. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett., 157: 105-112, 2000.
24. Kikuchi, T., and Crystal, R. G. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum. Gene Ther., 10: 1375-1387, 1999.
25. Maemondo, M., Narumi, K., Saijo, Y., Usui, K., Tahara, M., Tazawa, R., Hagiwara, K., Matsumoto, K., Nakamura, T., and Nukiwa, T. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol. Ther., 5: 177-185, 2002.
26. Matsuki, H., Yonezawa, K., Obata, K., Iwata, K., Nakamura, H., Okada, Y., and Seiki, M. Monoclonal antibodies with defined recognition sequences in the stem region of CD44: Detection of differential glycosylation of CD44 between tumor and stroma cells in tissue. Cancer Res., 63: 8278-8283, 2003.
27. Nomura, H., Fujimoto, N., Seiki, M., Mai, M., and Okada, Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int. J. Cancer, 69: 9-16, 1996.
28. Ueda, J., Kajita, M., Suenaga, N., Fujii, K., and Seiki, M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene, 22: 8716-8722, 2003.
29. Lehti, K., Lohi, J., Valtanen, H., and Keski-Oja, J. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem. J., 334 (Pt 2): 345-353, 1998.
30. Yana, I., and Weiss, S. J. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol. Biol. Cell, 11: 2387-2401, 2000.
31. Seiki, M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett., 194: 1-11, 2003.
32. Turk, B. E., Huang, L. L., Piro, E. T., and Cantley, L. C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat. Biotechnol., 19: 661-667, 2001.
33. Egeblad, M., and Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2: 161-174, 2002.
34. Baker, A. H., Edwards, D. R., and Murphy, G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell. Sci., 115: 3719-3727, 2002.